Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Nephrology
Published in: Journal of Nephrology 5/2022

07-06-2022 | Vaccination | Research Letter

Humoral immunity against Covid-19 six months after the Pfizer BNT162b2 vaccine in hemodialysis patients: data from five dialysis units. Is there a protective role for hemodiafiltration in the Covid-19 pandemic?

Authors: Teresa Chuva, Teresa Santos, Francisco Gonçalves, Luísa Costa, Elisabete Alves, Inês Neves, Ana Paiva, Berta Carvalho, Tânia Sousa, António Ramalheiro, José Maximino, Luísa Vila-Afonso, Luís Vidal Pinheiro, Otília Corrêa, Alfredo Loureiro

Published in: Journal of Nephrology | Issue 5/2022

Login to get access

Excerpt

Global vaccination against SARS-CoV2 began in 2021, but only a small proportion of patients with renal disease have been included in clinical trials, and long-term data on dialysis patients are still scant. These immunocompromised patients also have a poorer response to other vaccines [1], hence it is important to understand if there is a need for a tailored immunization protocol against SARS-CoV2. …
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
5.
Metadata
Title
Humoral immunity against Covid-19 six months after the Pfizer BNT162b2 vaccine in hemodialysis patients: data from five dialysis units. Is there a protective role for hemodiafiltration in the Covid-19 pandemic?
Authors
Teresa Chuva
Teresa Santos
Francisco Gonçalves
Luísa Costa
Elisabete Alves
Inês Neves
Ana Paiva
Berta Carvalho
Tânia Sousa
António Ramalheiro
José Maximino
Luísa Vila-Afonso
Luís Vidal Pinheiro
Otília Corrêa
Alfredo Loureiro
Publication date
07-06-2022
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 5/2022
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-022-01350-9

Other articles of this Issue 5/2022

Journal of Nephrology 5/2022 Go to the issue

Case Report

Long term central venous catheters for haemodialysis causing an extra-cardiac right-to-left shunt

Art in the Ward

Filling the gaps: the home dialysis discussion

original Article

Dialysis symptom index burden and symptom clusters in a prospective cohort of dialysis patients

Original Article

Humoral immunogenicity and tolerability of heterologous ChAd/BNT compared with homologous BNT/BNT and ChAd/ChAd SARS-CoV-2 vaccination in hemodialysis patients

Technical Note

Use of ultrasound to confirm guidewire position in hemodialysis catheter implantation

Systematic Reviews

Salivary changes in chronic kidney disease and in patients undergoing hemodialysis: a systematic review and meta-analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits